Beetroot for High Cholesterol
Beetroot supplementation does not effectively lower LDL cholesterol or improve lipid profiles in adults with elevated cholesterol, and established evidence-based therapies—statins, ezetimibe, and lifestyle modification—should be used instead.
Evidence Against Beetroot for Cholesterol Management
The most comprehensive systematic review and meta-analysis of randomized controlled trials found that beetroot consumption had no significant effect on any lipid parameter 1:
- Total cholesterol: mean difference 1.25 mg/dL (95% CI: -0.03 to 2.53) – not significant 1
- Triglycerides: mean difference -0.47 mg/dL (95% CI: -1.16 to 0.21) – not significant 1
- HDL cholesterol: mean difference 0.54 mg/dL (95% CI: -0.13 to 1.21) – not significant 1
- LDL cholesterol: mean difference -0.48 mg/dL (95% CI: -1.04 to 0.09) – not significant 1
Subgroup analyses by health condition, form of beetroot (juice vs. powder), and intervention type showed no significant differences, leading investigators to conclude that beetroot cannot be categorized as effective supplementation for lipid profile adjustment 1.
A 12-week randomized trial in type 2 diabetes patients using 24 mL concentrated beetroot juice daily showed no significant effect on fasting glucose, insulin, HbA1c, total cholesterol, LDL, HDL, triglycerides, or blood pressure after adjusting for baseline values 2. One small pilot study in dyslipidemic patients showed beetroot leaves and stalk juice attenuated HDL reduction after a high-fat meal, but this was an acute postprandial effect with no sustained lipid-lowering benefit 3.
Guideline-Recommended Lipid Management
Risk Stratification and LDL-C Goals
Adults with elevated cholesterol require risk-based LDL-C targets 4:
| Risk Category | LDL-C Goal | Statin Initiation Threshold |
|---|---|---|
| CHD-risk equivalent (diabetes age 40–75, other atherosclerotic disease, 10-year risk ≥20%) | <100 mg/dL | ≥130 mg/dL (consider at ≥100 mg/dL) |
| Moderately high risk (10–20% 10-year risk, ≥2 risk factors) | <130 mg/dL (optional <100 mg/dL) | ≥130 mg/dL |
| Intermediate risk (<10% 10-year risk, ≥2 risk factors) | <130 mg/dL | ≥160 mg/dL |
| Low risk (0–1 risk factor) | <160 mg/dL | ≥190 mg/dL |
Very high-risk patients (recent ACS, progressive ASCVD, familial hypercholesterolemia) should achieve LDL-C <70 mg/dL or even <55 mg/dL 4.
First-Line Therapy: Therapeutic Lifestyle Changes
Initiate lifestyle modification immediately when LDL-C exceeds target 5:
- Saturated fat <7% of total calories and dietary cholesterol <200 mg/day 5, 6
- Soluble fiber 10–25 g/day and plant stanols/sterols 2 g/day to enhance LDL-lowering 6, 7
- Physical activity ≥30 minutes of moderate intensity on most days 5
- Weight management targeting BMI 18.5–24.9 kg/m² 5
Pharmacotherapy: Statins as First-Line
After 12 weeks of lifestyle therapy, start statin therapy if LDL-C remains above risk-specific thresholds 4:
- High-intensity statins (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) achieve ≥50% LDL-C reduction and are recommended for very high-risk and high-risk patients 4, 8
- Moderate-intensity statins (atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg) achieve 30–50% reduction for intermediate-risk patients 4
- Goal: at least 30–40% LDL-C reduction in high-risk or moderately high-risk patients 6
Add-On Therapy for Inadequate Response
If LDL-C remains above goal on maximally tolerated statin 4, 8:
- Add ezetimibe 10 mg daily (first-line add-on; reduces MACE by ~6% over 6 years) 8
- If LDL-C still ≥70 mg/dL after 4–6 weeks, add a PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran; reduces MACE by ~15% over 2–3 years) 8
- Bempedoic acid 180 mg daily is an alternative for statin-intolerant patients (lowers LDL-C ~20% and reduces MACE) 8
Common Pitfalls
- Do not delay statin initiation in high-risk patients awaiting lifestyle results; start pharmacotherapy when LDL-C is markedly elevated 4
- Do not rely on LDL-C targets alone; always assess global cardiovascular risk with the Framingham Risk Score for patients with ≥2 risk factors 4
- Do not overlook metabolic syndrome; patients with obesity, inactivity, elevated triglycerides, or low HDL require intensive lifestyle intervention regardless of LDL-C level 4
- Do not use beetroot as a substitute for evidence-based lipid-lowering therapy; it lacks proven efficacy for cholesterol reduction 1